Creatine Boosts Dendritic Cells, Shrinks Melanoma Tumors in 1 Mouse Model
Updated
Updated · conexiant.com · Jul 8
Creatine Boosts Dendritic Cells, Shrinks Melanoma Tumors in 1 Mouse Model
3 articles · Updated · conexiant.com · Jul 8
Summary
Tumor dendritic cells sharply increased the creatine transporter, and mice lacking that transporter showed weaker antigen presentation, lower inflammatory signaling and poorer CD8 T-cell priming against cancer.
Creatine supplementation reversed those defects by raising ATP reserves and supporting NF-κB signaling during immune activation, producing stronger tumor-specific T-cell responses and smaller B16 melanoma tumors.
RGX-202 blockade of the transporter also damped NF-κB activity and impaired dendritic-cell activation, reinforcing the study's proposed creatine-dependent immune pathway.
Human monocyte-derived dendritic cells responded similarly: creatine improved activation of NY-ESO-1-specific T cells, suggesting the mechanism may extend beyond mice.
The findings point to a possible metabolic lever for overcoming cancer immunotherapy resistance, though the work is limited to 1 mouse tumor model and key mechanisms remain unclear.